Background: Pulmonary #fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population. There is growing global interest in PF, evident from a nearly threefold increase in PF-related research publications over the last 15 years. Idiopathic PF, connective tissue disease-related ILD, sarcoidosis and hypersensitivity pneumonitis rank as the top four… Continue reading Global perspective on pulmonary fibrosis: epidemiology, regional variations, gaps in care and future directions
Tag: fibrosis
Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition
Idiopathic pulmonary fibrosis ( #IPF ) is a progressive, fatal lung disease that develops in response to chronic epithelial injury. Unlike injury-induced homeostatic lung repair during which fibroblasts undergo apoptosis and clearance, the lungs of IPF patients continue to accumulate apoptosis-resistant, pro-fibrotic, extracellular matrix-producing fibroblasts. Here, we show that prevention of PDGFRα+ fibroblast apoptosis by… Continue reading Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
To the editorBetween the end of 2020 and the beginning of 2021, the first mRNA vaccines against COVID-19 received approval for emergency use by the World Health Organization (WHO). Patientsaffected by fibrotic interstitial lung disease (ILD) were granted priority access to vaccination,as these patients may develop severe complications after SARS-CoV-2 infection and carry ahigher risk… Continue reading COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Using an aptamer-based profiling platform we identified an individual and panel of circulating proteins that non-invasively identify significant fibrosis at-risk NASH in 316 adults with NAFLD.•An 8-protein panel can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage 2-4 with an AUROC 0.87- 0.89.•The ADAMTSL2 protein alone can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage… Continue reading ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics… Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
2 Medical News 